Sat, Jan 31, 2015, 11:56 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Teva Pharmaceutical Industries Limited Message Board

  • oedd1159 oedd1159 Jan 4, 2014 1:46 PM Flag

    Credit Suisse

    I a recent released study Credit Suisse forecasted that Copaxone Sales would decrease in 2019 to just 400 M from the current 4 B .If that is so that means a yearly reduction in revenues of 360 M roughtly around 9%

    Now chose a recently issue revenue decrease by Teva say from 4 q 2012 to 1 q 2013 and you will realize that in spite of a revenue slide of 6.6 % price did not follow suit in fact Teva price increased from 37 to 39.5 .

    I think that if Teva keeps pouring new pharmacologic entities into the stream here and there in the next 7 years i think that will do . (its R&D budget will ensure that ) Imao.


    * Credit Suisse also foresees an increase in sales of Laquinimod by 1B by the same period.

    ** Credit Suisse was one of the best stock analyst performers for 2013.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
56.86-0.70(-1.22%)Jan 30 4:05 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.